Analytical Data
-
Gene name
tPA
- Application
-
Alternative Names
tPA；Tissue-type plasminogen activator
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P00750
-
Expression Region
36-562aa
-
AA Sequence
SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKS CSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISY RGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRD SKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGAS CLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRR LTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRS PGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQ KFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPAD LQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRT VTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGL GCGQKDVPGVYTKVTNYLDWIRDNMRPVDHHHHHH
-
Molecular Weight
61 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Tissue Plasminogen Activator (tPA) is a crucial recombinant protein that plays a significant role in the medical management of thrombotic conditions, particularly in the treatment of acute ischemic stroke. Originally isolated from human endothelial cells, tPA functions as a serine protease that catalyzes the conversion of plasminogen to plasmin, leading to the dissolution of fibrin clots. Its efficacy in restoring blood flow and reducing neuronal damage in stroke patients has made it a standard therapeutic agent since its approval in the early 1990s. Research in the field has focused on optimizing the pharmacokinetics and safety profile of tPA, as well as exploring its potential applications in other thrombotic disorders, such as myocardial infarction and pulmonary embolism. Additionally, scientists are investigating modifications to enhance its specificity and reduce the risk of hemorrhagic complications, a significant concern associated with its use. Advances in biotechnology have facilitated the production of recombinant tPA, allowing for greater availability and consistency in treatment. Ongoing studies aim to better understand the molecular mechanisms of tPA action, leading to improved therapeutic strategies and potentially identifying novel indications for its use. Overall, the research surrounding tPA continues to evolve, reflecting its importance in the realm of cardiovascular and cerebrovascular medicine.
